Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to -$30.6 million.

  • Avalo Therapeutics' Consolidated Net Income fell 23293.83% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 115506.41%. This contributed to the annual value of -$35.1 million for FY2024, which is 1136.51% down from last year.
  • Latest data reveals that Avalo Therapeutics reported Consolidated Net Income of -$30.6 million as of Q3 2025, which was down 23293.83% from -$20.8 million recorded in Q2 2025.
  • Avalo Therapeutics' Consolidated Net Income's 5-year high stood at $98.5 million during Q2 2024, with a 5-year trough of -$121.3 million in Q1 2024.
  • For the 4-year period, Avalo Therapeutics' Consolidated Net Income averaged around -$8.7 million, with its median value being -$8.2 million (2023).
  • Examining YoY changes over the last 5 years, Avalo Therapeutics' Consolidated Net Income showed a top increase of 130179.42% in 2024 and a maximum decrease of 111838.27% in 2024.
  • Quarter analysis of 4 years shows Avalo Therapeutics' Consolidated Net Income stood at -$65000.0 in 2021, then tumbled by 12466.15% to -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then grew by 13.34% to -$30.6 million in 2025.
  • Its Consolidated Net Income was -$30.6 million in Q3 2025, compared to -$20.8 million in Q2 2025 and -$13.1 million in Q1 2025.